Get All Access for FREEMarket News & Research,
Live Transcripts & Audio,
and a whole lot more…
$BAX's cash provided from operating activities for FY15 decreased to $1.65Bil from $3.22Bil last year, while cash used in investing activities increased to $1.81Bil from $1.54Bil. Cash used in financing activities declined to $357MM from $1.40Bil in the previous year.
$BAX announced the FDA approval of Bivalirudin in 0.9% Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.
$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.
$BAX presented new data on Sharesource telehealth platform in helping the clinical management of peritoneal dialysis (PD) patients. The exploratory studies show how Sharesource data may provide an early indicator of impending peritonitis, or evidence of PD catheter dysfunction.
$BAX now projects 4Q17 revenues to be negatively impacted by about $70MM due to the temporary manufacturing disruptions resulting from Hurricane Maria. For 4Q17, $BAX sees sales growth of 4-5% on a reported basis, about 2% on a constant currency basis and 1-2% operationally. $BAX sees EPS, before special items, of $0.56-0.59.
$BAX's Renal sales for 3Q17 were about $1Bil, representing an increase of 3% on both a reported basis and constant currency basis. Operationally, Renal sales advanced 6% in the quarter driven by improved performance across all major product lines and therapies globally.
$BAX's global sales for Hospital Products for 3Q17 advanced 7% from last year. Performance benefited from continued strength in U.S. fluid systems business as well as favorable demand for injectable pharmaceuticals. Sales also benefited from increased sales of anesthesia and critical care products as well as hospital pharmacy compounding services.
$BAX's sales within the U.S. for 3Q17 were about $1.1Bil, advancing 8%. International sales totaled about $1.6Bil, representing a 5% increase on a reported basis and a 4% rise on a constant currency basis. Baxter's operational sales rose 7% in the U.S. and 6% internationally.
$BAX reported a jump in 3Q17 earnings driven by lower costs and expenses as well as its continued focus on disciplined execution. Net income rose to $251MM or $0.45 per share from $130MM or $0.24 per share last year. Net sales grew 6% to $2.71Bil. Adjusted EPS increased 14% to $0.64.
$BAX provided updates regarding recovery efforts following the impact of Hurricane Maria on its Puerto Rico operations. While $BAX now anticipates a reduction in revenue for 4Q17 as a result of the storm, the company expects to mitigate the related earnings impact through positive performance in other areas of the business.
$BAX announced enrollment of first patients in two new clinical trials for a unique expanded hemodialysis (HDx) therapy enabled by Theranova. Baxter’s HDx therapy enabled by Theranova was designed to remove large molecular weight toxins that have been associated with inflammation and cardiovascular health for end-stage renal disease patients.
Healthcare products provider $BAX has completed the acquisition of pharmaceutical company Claris Injectables. The $625MM transaction was financed through a combination of cash and debt. The company expects the acquisition to be modestly accretive to its adjusted earnings in 2017, and increasingly accretive thereafter.
$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.
As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.
$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.
$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.
$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.